遺伝子治療薬の世界市場:眼疾患

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DELVGT502004)
◆英語タイトル:Gene Therapy Ophthalmology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape
◆発行会社/調査会社:DelveInsight
◆商品コード:DELVGT502004
◆発行日:2015年1月
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:130
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single User(1名使用)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD9,000 ⇒換算¥1,017,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[遺伝子治療薬の世界市場:眼疾患]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Summary
DelveInsight’s Report: Gene Therapy Ophthalmology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Gene Therapy Ophthalmology Report provides the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.

Report facts
DelveInsight Gene Therapy Ophthalmology Report: “Gene Therapy Ophthalmology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape” provides in depth insights into the Ophthalmology gene therapy. It has covered 30+ gene therapies covering 25+ Pharmaceutical companies. Studies are performed for approximately 30+ specific indications under Ophthalmology. The Companies are utilizing 15 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 85% for viral vectors, 10% for RNAi therapeutics and 5% for Non Viral vectors. The Report is also giving early winners of the Ophthalmology gene therapy market using DelveInsight proprietary Matrix Model.

Reports Highlights:
• Global Gene Therapy Overview & Pipeline Insights
• Trends in gene therapy partnering deals
• Current Prominent Research Areas and Key Players
• Companies Targeting Prominent Therapeutic Areas
• Number of Gene Therapies in Clinical Trials
• Number of Gene Therapies by Vectors used
• Technology and their innovative Companies
• Early Market Winners for Gene Therapy

Scope
• A snapshot of the global Gene therapy market scenario, market trends & drivers, manacles of gene therapy.
• A review of the marketed Gene therapy products and marketing status
• Coverage of global gene therapies under development across the globe covering territories
• Competitive landscape of investigational products for key players and key therapy areas.
• The Gene Therapy report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information
• The Report also provides the pre-clinical and clinical outcomes of the gene therapies
• The Report has covered the vector used, target genes, localization of gene and detailed mechanism of action
• Report has highlighted the licensing opportunities and funding details for gene therapies
• The report also gives the information of dormant and discontinued pipeline projects
• Market Analytics of Gene Therapies using DelveInsight Propriety Model.

Reason to Buy
• Complete Market and Pipeline intelligence and complete understanding over therapeutics development for gene therapy
• Devise corrective measures for pipeline projects by understanding Therapy area specific gene therapies
• Developing strategic initiatives to support your gene therapy development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Evaluate the marketing and pipeline strategy for gene therapies and their Funding availabilities.
• Identifying the upcoming leaders in the gene therapy market in the coming years.
• Getting a first mover advantage by identifying the early market winners for clinical and preclinical gene therapies.

*** レポート目次(コンテンツ)***

[Table of Contents]

Introduction
Global Gene Therapy Market & Pipeline Insight Market Highlight
Gene Therapy- An Upcoming Innovation of Genetic Medicines
Internationally Recognized Gene Symbols
Driving Factors for Growing Popularity of Gene Therapy
Market Manacles for Gene Therapy
Current Research Therapeutic Areas in Gene Therapy Market
Ex vivo and In vivo Approaches of Gene Therapy
Types of Vectors developed for Gene Therapy
Marketed and Pipeline Drugs for Gene Therapy
Marketed Products Scenario for Gene Therapies
Rexin G Profile
Technology Description
Funding Agreement
Gendicine Profile
Technology Description
Funding Agreement
Glybera Profile
Technology Description
Funding Agreement
Assessment of Marketed Drugs by Therapeutic Approach
Assessment of Marketed Drugs by Route of Administration
Assessment of Marketed Drugs by Delivery System
Pipeline Gene Therapy Products under Ophthalmology
Gene Therapy Products Distribution on the Basis of Delivery System Developed
Gene Therapy Products Distribution on the Basis of Genetic Material Transfer Techniques
Gene Therapies Profiles
Product Description
Product Technology Description
Product Funding Agreement
Product Pre-clinical Outcomes
Product Clinical Outcomes
Discontinued Products
Dormant Products
DelveInsight Competitive Matrix
Early Winners for Gene therapy
Report Methodology
Secondary Research
Primary Research
Expert Panel Validation
About DelveInsight
Contact Us

[LIST OF TABLES]

Table 1: Human Genome Statistics, 2015
Table 2: Statistics for Various Locus Type under Non-Coding RNA, 2015
Table 3: Statistics for Various Locus Type under Pseudogenes, 2015
Table 4: Statistics for Various Locus Type under Non-Coding RNA, 2015
Table 5: Most Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Table 6: Less Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Table 7: Number of Companies Targeting Therapeutic Areas for Gene Therapy, 2015
Table 8: Number of Gene Therapy Products of Prominent Therapeutic Areas in Clinical Trials, 2015
Table 9: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%), 2015
Table 10: Distribution of Companies Based on the Genetic Material Transfer Techniques (%), 2015
Table 11: Number of Gene Therapy Products Addressed to Different Types of Vectors, 2015
Table 12: Marketed and Pipeline Gene Therapy Products, 2015
Table 13: Therapeutic Areas of Marketed Gene Therapy, 2015
Table 14: Number of Gene Therapy Products under Development for Ophthalmology, 2015
Table 15: Number of Gene Therapy Products Addressed to Different Types of Vectors Ophthalmology, 2015
Table 16: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%) for Ophthalmology, 2015
Table 16: Companies and Number of Gene Therapies for Ophthalmology, 2015
Table 17: Companies and Number of Gene Therapies in Clinical Trials for Ophthalmology, 2015
Table 18: Indications and Number of Gene Therapies in Clinical Trials for Ophthalmology, 2015
Table 19: Discontinued Products, 2015
Table 20: Dormant Products, 2015

[LIST OF FIGURES]

Figure 1: Human Genome Statistics, 2015
Figure 2: Statistics for Various Locus Type under Non-Coding RNA, 2015
Figure 3: Statistics for Various Locus Type under Pseudogenes, 2015
Figure 4: Statistics for Various Locus Type under Non-Coding RNA, 2015
Figure 5: Most Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Figure 6: Less Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Figure 7: Number of Companies Targeting Therapeutic Areas for Gene Therapy, 2015
Figure 8: Number of Gene Therapy Products of Prominent Therapeutic Areas in Clinical Trials, 2015
Figure 9: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%), 2015
Figure 10: Distribution of Companies Based on the Genetic Material Transfer Techniques (%), 2015
Figure 11: Number of Gene Therapy Products Addressed to Different Types of Vectors, 2015
Figure 12: Marketed and Pipeline Gene Therapy Products, 2015
Figure 13: Therapeutic Areas of Marketed Gene Therapy, 2015
Figure 14: Number of Gene Therapy Products under Development for Ophthalmology, 2015
Figure 15: Number of Gene Therapy Products Addressed to Different Types of Vectors for Ophthalmology, 2015
Figure 16: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%) for Ophthalmology, 2015
Figure 16: Companies and Number of Gene Therapies for Ophthalmology, 2015
Figure 17: Companies and Number of Gene Therapies in Clinical Trials for Ophthalmology, 2015
Figure 18: Indications and Number of Gene Therapies in Clinical Trials for Ophthalmology, 2015



*** レポートのキーワード ***

眼疾患、遺伝子治療、製薬、パイプライン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DELVGT502004 )"遺伝子治療薬の世界市場:眼疾患" (英文:Gene Therapy Ophthalmology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。